Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

AIDS

Volumn 15, Issue 8, 2001, Pages 1009-1018

  Sadler, Brian M ^c   Piliero, Peter J ^a   Preston, Sandra L ^b   Lloyd, Peggy P ^c   Yu, Lou ^c   Stein, Daniel S ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE

Author keywords

Amprenavir; Drug interaction; Pharmacokinetics; Protease inhibitors; Ritonavir; Safety

Indexed keywords

AMPRENAVIR; CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

ADMINISTRATION, ORAL; ADULT; BODY MASS INDEX; CARBAMATES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; NAUSEA; RITONAVIR; STATISTICS, NONPARAMETRIC; SULFONAMIDES;

EID: 0006179308     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105250-00009     Document Type: Article

References (34)

1. 1. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. 2. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. 3. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
4. 4. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
5. 5. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel. JAMA 2000, 283:381-390.
6. 6. Mehta S, Moore R, Graham N. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
7. 7. Hirschhorn L, Stone V, Boswell S. Discontinuation (D/C) of protease inhibitor (PI) therapy: reasons and risk factors, XII International Conference on AIDS, Geneva, June 1998 [abstract 12443].
8. 8. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999, 13:1099-107.
9. 9. Stein DS, Sadler B, Sale M. Pharmacodynamic effects of amprenavir (APV) + ritonavir (RTV) on different viral populations. First International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, March 2000 [abstract 5.2].
10. 10. Stellrecht K, Drusano G, Stein D, Bilello J. Plasma alpha-1 acid glycoprotein is reduced in HIV-infected patients co-infected with hepatitis C virus (HCV). Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 84].
11. 11. Kremer J, Wilting J, Janssen Drug binding to human alpha-1 glycoprotein in health and disease. Pharmacol Rev 1998, 40; 1-47.
12. 12. Sadler B, Gillotin C, Lou Y, Stein D. Effect of demographic, laboratory, and clinical covariates on the pharmacokinetics (PK) of amprenavir (APV). Sixth Conference on Retroviruses and Opportunistic infections. Chicago, Illinois, January-February 1999 [abstract 375].
13. 13. Decker C, Laitinen Bridson G, Raybuck S, Tung R, Chaturvedi P. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998, 87:803-807.
14. 14. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P. Cytochrome P-450 isoenzyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September-October 1997 [abstract A60].
15. 15. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
16. 16. Hsu A, Granneman G, Cao G, et al. Pharmacokinetic interactions between two human immunodeficency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
17. 17. Hsu A, Granneman G, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998, 42:2784-2791.
18. 18. Burger D, Hugen P, Hofstede H, et al. Dose-finding study of a once-daily indinavir/ritonavir regimen in healthy volunteers. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [abstract 321].
19. 19. Saah A, Winchell G, Senuik M, Deutsch P. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089). 39th Interscience Conference on Anti-microbial Agents and Chemotherapy. San Francisco, September 1999 [abstract 329].
20. 20. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999, 13:F95-F99.
21. 21. Agouron Pharmaceuticals, Inc. Viracept-Product Information. Physician's Desk Reference. Montvale, NJ: Medical Economics Company Inc.; 2001.
22. 22. Piscitelli S, Bechtel C, Sadler B, Falloon J. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations, Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, California, January-February 2000 [abstract 78].
23. 23. Hsu A, Granneman G, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997, 41:898-905.
24. 24. Danner S, Carr A, Leonard J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
25. 25. Schapiro J, Winters M, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV infected patients. Ann Intern Med 1996, 124:1039-1050.
26. 26. Stein DS, Fish D, Bilello J, Preston S, Martineau G, Drusano G. A 24-week open-label phase l/ll evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996, 10:485-492.
27. 27. Acosta E, Henry K, Baken Page Fletcher C. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999, 19: 708-712.
28. 28. Fletcher C. Pharmacologic considerations for therapeutic success with antiviral agents. Ann Pharmacother1999, 33:989-995.
29. 29. Fletcher C, Brundage R, Remmel R, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000, 44:1029-1034.
30. 30. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997, 11:F95-F99.
31. 50. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September-October 1997 [abstract A-16].
32. 32. Sale M, Stein DS, Sadler B. Concomitant ritonavir decreases the clearance of amprenavir-a pharmacokinetic model of protease inhibitor interaction. First International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, March 2000 [abstract 2.10].
33. 33. Katlama C, Schneider L, Agher R, et al. Ritonavir (RTV)/amprenavir (APV) combination therapy in HIV infected patients who failed several protease inhibitor containing regimen. Fifth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, October 2000 [abstract 41].
34. 34. Wood R, Trepo, C, Livrozet JM, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naïve HIV-1 infected adults over 12 weeks (APV20001). Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 2001 [abstract 332].